NCT06577311View on ClinicalTrials.gov

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
COMBINATION_PRODUCT

Aminolevulinic acid hydrochloride 10% topical gel with Red Light

Participants will have their facial Cutaneous Squamous Cell Carcinoma in situ (SCCis) prepped then treated with Aminolevulinic acid hydrochloride 10% topical gel (Ameluz ®), followed by red light therapy administered for 13 minutes and 30 seconds to deliver the total desired light dose to the SCCis lesion.

Trial Locations (1)

33180

RECRUITING

Center for Clinical and Cosmetic Research, Aventura

Sponsors

Collaborators (1)

Biofrontera Inc.
All Listed Sponsors
collaborator

Biofrontera Inc.

INDUSTRY

lead

The Center for Clinical and Cosmetic Research

OTHER